{"id":5878,"date":"2024-11-11T07:51:38","date_gmt":"2024-11-11T13:51:38","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5878"},"modified":"2025-06-27T08:32:13","modified_gmt":"2025-06-27T13:32:13","slug":"nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/","title":{"rendered":"Nanoscope anuncia presentaciones en el Congreso de Terapias Avanzadas de EE. UU. en Filadelfia"},"content":{"rendered":"
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a011 de noviembre de 2024<\/span><\/span>\u00a0\u2014\u00a0Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraci\u00f3n macular relacionada con la edad (DMRE), anunci\u00f3 hoy presentaciones en el\u00a0Terapias avanzadas\u00a0EE.UU<\/span>\u00a0Congreso 2024<\/a>, siendo retenido\u00a012 y 13 de noviembre de 2024<\/span>, en Filadelfia, Pensilvania. Los detalles de las presentaciones son los siguientes:<\/p>\n

T\u00edtulo:\u00a0<\/b>Democratizar la terapia celular modificada gen\u00e9ticamente para enfermedades neurodegenerativas
Sesi\u00f3n:\u00a0<\/b>Pista 4: Terapia celular modificada gen\u00e9ticamente
Fecha de la sesi\u00f3n:\u00a0<\/b>Martes 12 de noviembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>De 13:30 a 13:50 EST\u00a0
Ubicaci\u00f3n:\u00a0<\/b>120B<\/span>,\u00a0Pensilvania<\/span>\u00a0centro de Convenciones
Presentador:\u00a0<\/b>Samarendra Mohanty, PhD, presidenta y directora cient\u00edfica<\/p>\n

T\u00edtulo del panel:\u00a0<\/b>Demostrar comparabilidad para respaldar la aprobaci\u00f3n regulatoria
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Pista 7: Fabricaci\u00f3n de vectores virales
Fecha de la sesi\u00f3n:\u00a0<\/b>Martes 12 de noviembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>De 15:30 a 16:10 EST<\/span>
Ubicaci\u00f3n:\u00a0<\/b>121B<\/span>,\u00a0Pensilvania<\/span>\u00a0centro de Convenciones
Miembro del jurado:\u00a0<\/b>Khandan Baradaran, PhD, vicepresidente s\u00e9nior de reglamentaci\u00f3n y calidad<\/p>\n

T\u00edtulo del panel:<\/b>\u00a0Vigilancia post comercializaci\u00f3n y seguimiento a largo plazo: \u00bfC\u00f3mo nos aseguramos de que se satisfacen las necesidades de los pacientes?
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Pista 9: Asuntos regulatorios y pol\u00edticas
Fecha de la sesi\u00f3n:\u00a0<\/b>Mi\u00e9rcoles 13 de noviembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>De 11:50 a. m. a 12:30 p. m., hora del este de EE. UU.
Ubicaci\u00f3n:\u00a0<\/b>120A,\u00a0Pensilvania<\/span>\u00a0centro de Convenciones
Miembro del jurado:\u00a0<\/b>Samarendra Mohanty, PhD, presidenta y directora cient\u00edfica<\/p>\n

T\u00edtulo del panel:\u00a0<\/b>Seguridad en la edici\u00f3n gen\u00e9tica
T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Pista 5: Terapia g\u00e9nica
Fecha de la sesi\u00f3n:\u00a0<\/b>Mi\u00e9rcoles 13 de noviembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>De 11:50 a. m. a 12:30 p. m., hora del este de EE. UU.<\/span>
Ubicaci\u00f3n:\u00a0<\/b>120 \u00b0C,\u00a0Pensilvania<\/span>\u00a0centro de Convenciones
Miembro del jurado:\u00a0<\/b>Khandan Baradaran, PhD, vicepresidente s\u00e9nior de reglamentaci\u00f3n y calidad<\/p>\n

T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Pista 9: Asuntos regulatorios y pol\u00edticas
Fecha de la sesi\u00f3n:\u00a0<\/b>Mi\u00e9rcoles 13 de noviembre de 2024<\/span>
Tiempo de sesi\u00f3n:\u00a0<\/b>3:35 p.m. EST<\/span>
Ubicaci\u00f3n:\u00a0<\/b>120A,\u00a0Pensilvania<\/span>\u00a0centro de Convenciones
Silla:\u00a0<\/b>Khandan Baradaran, PhD, vicepresidente s\u00e9nior de reglamentaci\u00f3n y calidad<\/p>\n

Acerca de Nanoscope Therapeutics, Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la compa\u00f1\u00eda anunci\u00f3 su plan de iniciar un\u00a0Presentaci\u00f3n de BLA para MCO-010 para tratar RP<\/a>\u00a0en el primer trimestre de 2025. La empresa ha completado el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Nov. 11, 2024\u00a0\u2014\u00a0Nanoscope Therapeutics, Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced presentations at the\u00a0Advanced Therapies\u00a0USA\u00a02024 congress, being held\u00a0November 12-13, 2024, in\u00a0Philadelphia, PA. Details for the presentations are as follows: Title:\u00a0Democratizing gene modified cell therapy for neurodegenerative diseasesSession:\u00a0Track 4: Gene Modified Cell TherapySession […]<\/p>\n","protected":false},"author":6,"featured_media":5879,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-11T13:51:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:32:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia\",\"datePublished\":\"2024-11-11T13:51:38+00:00\",\"dateModified\":\"2025-06-27T13:32:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/\"},\"wordCount\":370,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/\",\"name\":\"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg\",\"datePublished\":\"2024-11-11T13:51:38+00:00\",\"dateModified\":\"2025-06-27T13:32:13+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/11\\\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope anuncia presentaciones en el Congreso de Terapias Avanzadas de EE. UU. en Filadelfia - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-11-11T13:51:38+00:00","article_modified_time":"2025-06-27T13:32:13+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_AAO_Post_results.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia","datePublished":"2024-11-11T13:51:38+00:00","dateModified":"2025-06-27T13:32:13+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/"},"wordCount":370,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/","url":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/","name":"Nanoscope anuncia presentaciones en el Congreso de Terapias Avanzadas de EE. UU. en Filadelfia - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg","datePublished":"2024-11-11T13:51:38+00:00","dateModified":"2025-06-27T13:32:13+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_AdvancedTherapies_LI_2024._V2.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/11\/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5878"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5878\/revisions"}],"predecessor-version":[{"id":9010,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5878\/revisions\/9010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5879"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}